Fig. 5. Non-activated CART19 cells induce potent and durable remission of ALL at low doses.
a, Schematic of the xenograft model and CART19 cell treatment in NSG mice. b–d, Serial quantification of disease burden by bioluminescence imaging. b, Total BLI in mice treated with NTD control non-activated T cells. c, Total BLI in mice treated with a single high (2 × 106; left), medium (0.7 × 106; middle) or low (0.2 × 106; right) dose of non-activated T cells (d1) transduced as in Fig. 4e. d, Total BLI in mice treated with 3 × 106 CAR T cells stimulated with anti-CD3/CD28 microbeads and expanded over 9 d. For b–d, there were eight mice in each group. e, Time to initial anti-leukaemic response (that is, first reduction in bioluminescence) after infusion of non-activated CART19 cells relative to the T-cell dose. Data are mean ± s.d. f, Absolute CD45+ T-cell counts, measured using a TruCount assay, of peripheral blood collected from the mice in b–d on d10 following the T-cell transfer. *P = 0.0255; **P = 0.0011; ***P = 0.0002. g, Vector copy number, measured by qPCR and normalized to the DNA concentration, in peripheral blood collected on d10 following the T-cell transfer. *P = 0.0286. h, Absolute CD45+ T-cell counts, measured using a TruCount assay, of peripheral blood collected from the mice shown in b–d on d30 following the T cell transfer measured by a TruCount assay. ***P = 0.0002. f–h, The mean of each group is indicated by the solid black line. Groups were compared using a two-tailed unpaired Mann–Whitney test.